Related Experiment Video
Updated: Sep 16, 2025
08:43
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
Published on: January 31, 2020
6.9K
IRAK4 Targeting: A Breakthrough Approach to Combat Hidradenitis Suppurativa
Hui Zhang1, Zhi Liu1, Bozhao Qin2
1Department of Dermatology, The First Affiliated Hospital of Naval Medical University, Shanghai, People's Republic of China.
Biologics : Targets & Therapy
|July 7, 2025
Summary
Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a key role in hidradenitis suppurativa (HS) pathogenesis. Targeting IRAK4 offers a promising therapeutic strategy for this chronic inflammatory condition.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with significant impact on quality of life.
- Current HS treatments are limited, and its underlying pathogenesis is not fully understood.
- The IL-1R/TLR signaling pathway is implicated in inflammatory conditions like HS.
Purpose of the Study:
- To review the physiological functions of IRAK4 and its family members.
- To examine the role of the IRAK family, particularly IRAK4, in the IL-1R/TLR pathway.
- To analyze IRAK4's specific involvement in HS pathogenesis and evaluate IRAK4-targeted therapies.
Main Methods:
- Comprehensive literature review of IRAK4 and related signaling pathways.
- Systematic analysis of IRAK4's role in the IL-1R/TLR pathway.
- Review of current and emerging IRAK4-targeted drugs for HS treatment.
Main Results:
- IRAK4 is a critical kinase in the IL-1R/TLR signaling cascade.
- IRAK4 inhibition can reduce cytokine production, potentially alleviating HS symptoms.
- Emerging IRAK4 inhibitors, such as Zimlovisertib and KT-474, show therapeutic potential for HS.
Conclusions:
- IRAK4 is a validated therapeutic target for hidradenitis suppurativa.
- Targeting IRAK4 offers a novel approach to managing HS by modulating key inflammatory pathways.
- Further research and clinical trials are needed to establish the efficacy and safety of IRAK4 inhibitors in HS treatment.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
238
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
238
01:29Drugs for Treatment of Ulcerative Colitis in IBD
242
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
242
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
275
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
275
01:29Inflammatory Bowel Disease IV: Pharmacological Management
200
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
200
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
208
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
208
01:17Drugs for Treatment of Diarrhea-Predominant IBS
308
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
308